2025 Hypertension Thresholds Could Avert 200,000 US Deaths
This NHANES-based simulation quantifies the treatment gap and projected 10-year mortality benefit of the 2025 AHA/ACC risk-based antihypertensive thresholds for primary prevention.
📅 Journal publication: Aug 4, 2026(online Jul 29, 2026)·Last updated: Oct 7, 2026
New guidelines could prevent over 200,000 deaths in a decade.
The new 2025 hypertension guidelines by the American Heart Association and American College of Cardiology recommend earlier intervention, impacting treatment in adults with increased cardiovascular risk. Antihypertensive therapy showed a 23% reduction in all-cause mortality and a 50% reduction in cardiovascular mortality. Universal treatment could prevent over 200,000 all-cause and 160,000 cardiovascular deaths in 10 years. The study highlights a significant number of US adults newly eligible for hypertension treatment, emphasizing the impact of guideline adherence on mortality risk. Limitations include assuming full treatment uptake. Extending antihypertensive treatment per new guidelines could significantly reduce mortality rates.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.
Authors:Al-Jarshawi M, Bangalore S, Wijeysundera HC, Chew NW, Asher E, Mihailidou AS, Van Spall HGC, Mamas MA
Citation:Al-Jarshawi M, Bangalore S, Wijeysundera HC, et al. Population-Level 10-Year Implications of the New 2025 American Heart Association/American College of Cardiology Hypertension Guideline Recommendations for Primary Prevention in the United States: A NHANES-Based Cohort Study (2009-2018). Journal of the American Heart Association. 2026;15(15):e048616. doi:10.1161/JAHA.125.048616
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Want the full analysis?
Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.